Jamaica’s outlook revised to stable by Fitch after hurricane
Director Abhijit Y. Talwalkar of iRhythm Technologies, Inc. (NASDAQ:IRTC) sold a total of 5,512 shares of common stock on November 10, 2025, for approximately $924,961. The sales were executed in multiple transactions with prices ranging from $172.3184 to $177.85. The stock is currently trading at $179.12, representing a remarkable 95.53% gain year-to-date and 102.19% over the past year, though InvestingPro analysis suggests the stock is trading above its Fair Value.
Talwalkar also exercised options to acquire 5,312 shares of iRhythm Technologies common stock at a price of $10.71, for a total value of $56,891.
Following these transactions, Talwalkar directly owns 20,299 shares of iRhythm Technologies.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on May 12, 2025.
In other recent news, iRhythm Technologies reported impressive third-quarter earnings, with revenue reaching $192.9 million, a 30.7% increase from the previous year, and surpassing consensus estimates by approximately $8 million. The company also reported adjusted earnings per share of $0.06, significantly outperforming the analyst estimate of -$0.32. Following these strong results, several analyst firms have raised their price targets on iRhythm Technologies. Freedom Capital Markets increased its price target to $220, while Needham raised theirs to $244, citing the company’s revenue results and updated guidance. BTIG also adjusted its price target to $215, maintaining a Buy rating, and Canaccord Genuity set a new target of $212, highlighting the company’s record quarters for its Zio Monitor and Zio AT products. These developments reflect the company’s continued strength in its core business and successful integration of its products into electronic health records.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.